A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19

Phase 2 Unknown 40 enrolled Stemedica Cell Technologies, Inc. bioRASI, LLC · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase II multi-center, double-blind, placebo-controlled, randomized study in Patients with moderate to severe lung injury due to COVID-19 or other potential viral and bacterial pathogens.

Timeline

Start: 2021-03-20
Primary completion: 2022-09-30
Completion: 2022-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	hMSC	Cell therapy	—	Intravenous

A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19

Summary

Timeline

Drugs

Indications